Former Chief Medical Officer · Kura Oncology, Inc. (KURA)

Stephen Dale

A named executive officer of Kura Oncology in every fiscal year CompBrief holds from FY2020 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$2,508,675

Salary $575,140Stock awards $0

FY2022: $3,443,477

2nd of 4 named executive officers at Kura Oncology by FY2024 total.

4 named officers on file for Kura Oncology, FY2024

Stephen Dale’s pay file — $29

  • 4 fiscal years of pay, line by line
  • 7 equity grants, each cited to its filing
  • KURA’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Kura Oncology’s whole pay program stands against its peers

  • Kura Oncology’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on KURA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 11, 2025 (DEF 14A).

Free

Get Stephen Dale’s full pay file as a PDF — free

More than this page: up to 10 years of Stephen’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Stephen Dale compensation by year

Kura Oncology Summary Compensation Table · all 4 fiscal years held
In US dollars, as Kura Oncology reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021FY2022FY2024
Salary$158,602$489,014$463,600$575,140
Bonus$150,000$119,595$47,515$0
Stock awards$0$0$522,135$0
Option awards$2,887,220$2,117,100$2,236,927$1,632,903
Non-equity incentive$81,782$183,851$161,100$283,382
Pension and deferred compensation$0$0$0$0
All other$8,550$19,122$12,200$17,250
Total$3,286,154$2,928,682$3,443,477$2,508,675

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Kura Oncology, Inc. DEF 14A filed April 11, 2025, accession 0000950170-25-053335, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Kura Oncology, Inc. filed document, accession 0000950170-25-053335. Every figure is read from that document and cited to the page and table it appears in. Filed April 11, 2025.

$3.3M
$2.9M
$3.4M
$2.5M
FY20
FY21
FY22
FY24
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
PSU247,500$2,155,725—
RSU18,450$160,700—
RSU17,344$151,066—
Option2,084—$32.80
Option70,688—$14.15
Option100,209—$11.99
Option142,605—$15.36

Per the Outstanding Equity Awards at Fiscal Year-End table in Kura Oncology, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Kura Oncology’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Troy WilsonPresident and Chief Executive Officer$6,239,098
Stephen Dale · this pageFormer Chief Medical Officer$2,508,675
Kathleen FordChief Operating Officer$2,501,838
Teresa BairChief Legal Officer and Secretary$2,271,872

The full Kura Oncology compensation record

free company brief

This page is one person within Kura Oncology's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Kura Oncology proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Kura Oncology's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Stephen Dale's compensation dossier · One-time report. No refunds.